公开(公告)号：US11186618B2

公开(公告)日：2021-11-30

申请号：US16335625

申请日：2017-09-21

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Yasuo Yoshioka

IPC: C07K14/415 ,  A61K9/00 ,  C07K14/36 ,  C07K14/315 ,  C07K19/00 ,  A61P37/04 ,  C07K7/06 ,  A61K47/50 ,  A61K39/00 ,  C12P21/02 ,  C12N15/09

Abstract: The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

公开(公告)号：US09493550B2

公开(公告)日：2016-11-15

申请号：US14505515

申请日：2014-10-03

Applicant: Osaka University ,  The Research Foundation for Microbial Diseases of Osaka University

Inventor： Kazuyoshi Ikuta ,  Ritsuko Koketsu ,  Yoshinobu Okuno ,  Mikihiro Yunoki ,  Shoji Ideno ,  Masatoshi Oshita ,  Motoki Kuhara ,  Masatoshi Momota

IPC: C07K16/10 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76

Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

公开(公告)号：US20240091341A1

公开(公告)日：2024-03-21

申请号：US18032545

申请日：2021-10-18

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Inventor： Yasuo YOSHIOKA

IPC: A61K39/215 ,  A61P37/04 ,  C07K14/005 ,  C12N9/24

CPC classification number: A61K39/215 ,  A61P37/04 ,  C07K14/005 ,  C12N9/2402 ,  C12Y302/01018 ,  A61K2039/543

Abstract: The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.

公开(公告)号：US20210338798A1

公开(公告)日：2021-11-04

申请号：US16316186

申请日：2017-07-11

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Takao Fujimoto ,  Junji Fujita

IPC: A61K39/145 ,  C12N7/00

Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).

公开(公告)号：US20210261964A1

公开(公告)日：2021-08-26

申请号：US17260418

申请日：2019-07-18

Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  OSAKA UNIVERSITY ,  TEIKYO UNIVERSITY

Inventor： Taiki AOSHI ,  Shohei KOYAMA ,  Ryo SUZUKI

IPC: C12N15/117 ,  A61K9/107 ,  A61K31/7088 ,  A61K47/28 ,  A61K47/24 ,  A61K47/54 ,  A61P35/00

Abstract: An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.

公开(公告)号：US20190300585A1

公开(公告)日：2019-10-03

申请号：US16335625

申请日：2017-09-21

Applicant: The Research Foundation for Microbial Diseases of Osaka University

Inventor： Yasuo Yoshioka

IPC: C07K14/415 ,  C07K14/36 ,  A61K9/00

Abstract: The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

公开(公告)号：US20180223326A1

公开(公告)日：2018-08-09

申请号：US15579953

申请日：2016-06-17

Applicant: The Research Foundation For Microbial Diseases Of Osaka University ,  Osaka University

Inventor： Yukihiro Akeda ,  Hiroshi Miyatake ,  Zhenyu Piao ,  Yuka Koizumi

IPC: C12Q1/18

CPC classification number: C12Q1/18 ,  C07K16/12 ,  C12N1/20 ,  G01N2333/3156

Abstract: The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.

公开(公告)号：US09605053B2

公开(公告)日：2017-03-28

申请号：US15017246

申请日：2016-02-05

Applicant: Fujita Health University ,  The Research Foundation for Microbial Diseases of Osaka University

Inventor： Yoshikazu Kurosawa ,  Yoshitaka Iba ,  Nobuko Ohshima ,  Yoshinobu Okuno

IPC: A61K39/395 ,  A61K39/42 ,  A61K39/00 ,  A61P31/16 ,  C07K16/18 ,  C07K16/10

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/00

Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

公开(公告)号：US20160200799A1

公开(公告)日：2016-07-14

申请号：US14913613

申请日：2014-08-20

Applicant: FUJITA HEALTH UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  PERSEUS PROTEOMICS INC.

Inventor： Yoshikazu KUROSAWA ,  Nobuko OSHIMA ,  Yoshinobu OKUNO ,  Katsuyuki MITOMO ,  Katsushi KOUDA

IPC: C07K16/10

CPC classification number: C07K16/1018 ,  C07K2317/76

Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).

Abstract translation: 本发明的目的是提供一种对流感病毒具有高结合活性和高中和活性的新型抗体。 本发明提供中和H1流感病毒和/或H5流感病毒的抗体，其中该抗体具有由定义的重链第一互补决定区（VH CDR1）构成的CDR的重链可变区，定义的重链 第二互补决定区（VH CDR2）和定义的重链第三互补决定区（VH CDR3）和轻链可变区，其具有由定义的轻链第二互补决定区（VL CDR2）和定义的 轻链第三互补决定区（VL CDR3）。

公开(公告)号：US09181328B2

公开(公告)日：2015-11-10

申请号：US14375675

申请日：2013-01-31

Applicant: OSAKA UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. ,  DEPARTMENT OF MEDICAL SCIENCES

Inventor： Mayo Yasugi ,  Motoki Kuhara ,  Jotika Boon-Long ,  Kazuhito Fujiyama ,  Ritsuko Koketsu ,  Kazuyoshi Ikuta

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

Abstract translation: 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。